Endoscopy 2019; 51(04): S166
DOI: 10.1055/s-0039-1681660
ESGE Days 2019 ePoster podium presentations
Friday, April 5, 2019 16:30 – 17:00: Preparation: sedation 1 ePoster Podium 7
Georg Thieme Verlag KG Stuttgart · New York

THE EFFECTIVENESS OF ORAL PHLOROGLUCIN AS PREMEDICATION FOR NON-SEDATIVE ESOPHAGOGASTRODUODENOSCOPY: A DOUBLE BLINDED, PLACEBO-CONTROLLED, RANDOMIZED CONTROLLED TRIAL

KB Cho
1   Keimyung University School of Medicine, Daegu, Korea, Republic of
,
YJ Lee
1   Keimyung University School of Medicine, Daegu, Korea, Republic of
,
JY Lee
1   Keimyung University School of Medicine, Daegu, Korea, Republic of
,
HJ Lee
1   Keimyung University School of Medicine, Daegu, Korea, Republic of
,
KS Park
1   Keimyung University School of Medicine, Daegu, Korea, Republic of
› Author Affiliations
Further Information

Publication History

Publication Date:
18 March 2019 (online)

Also available at
 

Aims:

Antispasmotic agents are commonly injected before esophagogastroduodenoscopy (EGD) to inhibit gastrointestinal peristalsis. This study aimed to evaluate the effectiveness of oral Phloroglucin (Flospan) as premedication for non-sedative EGD.

Methods:

A Prospective, double-blinded, placebo-controlled, randomized controlled trial was conducted at a single tertiary hospital. Subjects who scheduled to undergo non-sedative EGD were randomly assigned to receive oral Phloroglucin (Flospan) or placebo at 10 minutes before EGD. The degree of peristaltic movement was evaluated at the beginning and the end of the procedure by independent investigators.

Results:

Overall, 140 subjects were included in the study (Phloroglucin 70, placebo 70). The degree of peristalsis in Phloroglucin group was significantly lower compared with that of placebo at the beginning of the procedure (p= 0.02) and tended to be lower at the end of the procedure, although it did not show statistical significance (p= 0.064). The difficulty of intragastric observation was significantly lower in Phloroglucin group compared with placebo at the both time period (beginning of the procedure: p= 0.002, end of the procedure: p= 0.009). Both groups showed comparable adverse events, taste of the drug and willingness to take this premedication at the next examination.

Conclusions:

Overall, 140 subjects were included in the study (Phloroglucin 70, placebo 70, age mean ± SD, 66.31 ± 9.37, male 47.8%). The degree of peristalsis in Phloroglucin group was significantly lower compared with that of placebo at the beginning of the procedure (p= 0.02) and tended to be lower at the end of the procedure, although it did not show statistical significance (p= 0.064). The difficulty of intragastric observation was significantly lower in Phloroglucin group compared with placebo at the both time period (beginning of the procedure: p= 0.002, end of the procedure: p= 0.009). Both groups showed comparable adverse events, taste of the drug and willingness to take this premedication at the next examination.